Deals: Page 87
-
AZ buys rights to Almirall's respiratory portfolio in $2.1 billion deal
This deal signals AstraZeneca’s strength and independence.
By Nicole Gray • July 31, 2014 -
Can GSK overcome its Q2 blues by focusing on the future?
In the face of corruption allegations and diminished earnings forecasts, GSK is looking toward the horizon.
By Nicole Gray • July 29, 2014 -
Roche developing diagnostic test to support AZ's lung cancer candidate
Another example of how personalized medicine is improving cancer therapeutics.
By Nicole Gray • July 29, 2014 -
Boehringer and Zealand Pharma team up again to tackle obesity, diabetes
This is the second collaborative agreement between the two companies.
By Nicole Gray • July 29, 2014 -
Analysts on AbbVie's Shire deal: billions in tax savings
GlobalData analysts say moving business operations to Ireland will lower AbbVie’s taxes by 7%.
By Nicole Gray • July 29, 2014 -
Onco360 to distribute Gilead's Zydelig
PharMerica Corporation owns a substantial portion of Onco360.
By Nicole Gray • July 28, 2014 -
Reckitt Benckiser to spin off pharmaceutical business
RB Pharmaceuticals will become a stand-alone business, with the core company focusing on consumer health and hygiene.
By Nicole Gray • July 28, 2014 -
President Obama slams tax-inversion mergers: 'An unpatriotic tax loophole'
"We need to stop companies from renouncing their citizenship just to get out of paying their fair share of taxes," the president said Thursday.
By Sy Mukherjee • July 24, 2014 -
Lannett inks exclusive deal to distribute ACEON generic in the U.S.
Lannett will be the exclusive American distributor for a generic version of Symplmed Pharmaceuticals' hypertension drug ACEON.
By Nicole Gray • July 22, 2014 -
Major Allergan shareholder dumps stock in vote of no confidence
Capital Research and Management Co. is shedding almost all of its holdings in Botox-maker Allergan.
By Nicole Gray • July 22, 2014 -
AbbVie, Shire agree to $54.6 billion merger to slash corporate tax rate
This long-awaited cash-and-stock deal is a tax-inversion merger.
By Nicole Gray • July 18, 2014 -
Lilly, Immunocore partner to develop immunotherapy-based cancer treatments
Immunocore will receive up to $25 million for each candidate that is discovered and accepted by Lilly for clinical development.
By Nicole Gray • July 17, 2014 -
Dicerna Pharmaceuticals moving to Cambridge, MA
The company, which had the largest biotech IPO in MA so far this year, is doubling its footprint and moving into a former Pfizer space.
By Nicole Gray • July 17, 2014 -
Pfizer brings InnoPharma into the fold
The deal is worth up to $360 million and brings a strong portfolio of approved drugs and an even stronger pipeline.
By Nicole Gray • July 17, 2014 -
Oncology CROs merging to offer broader range of services
The goal of the merger between Chiltern and Ockham is to become the “premier specialized mid-tier CRO" for oncology services.
By Nicole Gray • July 16, 2014 -
Valeant moves forward with premerger notification to FTC, Allergan holds its own
The company is filing under the FTC’s Hart-Scott-Rodino Antitrust Improvement Act of 1976.
By Nicole Gray • July 15, 2014 -
AbbVie increases offer price for Shire
The deal is now valued at $53 billion.
By Nicole Gray • July 15, 2014 -
Abbott selling part of generics portfolio to Mylan
The transaction, which is valued at $5.3 billion, will close in Q1 2015
By Nicole Gray • July 15, 2014 -
HD Biosciences, Marshall U. launch Chinese drug venture
The partners will share costs, risks of development.
By Nicole Gray • July 14, 2014 -
Bayer, Oxford partner on gynecology research
Endometriosis and uterine fibroids affect millions of women worldwide.
By Nicole Gray • July 14, 2014 -
Pfizer, CliniWorks creating health management platform
It is being developed to deliver real-time healthcare that is both more efficient and more effective.
By Nicole Gray • July 11, 2014 -
Allergan making moves to be leaner
As Valeant’s hostile takeover efforts continue, Allergan starts cutting costs.
By Nicole Gray • July 10, 2014 -
Newly acquired Forest Labs lays off 190 employees in Missouri
With the Actavis takeover complete, changes are underway.
By Nicole Gray • July 10, 2014 -
AbbVie makes fresh bid for Shire
Richard Gonzalez, AbbVie's CEO, notes numerous synergies and sweetens the deal.
By Nicole Gray • July 9, 2014 -
AstraZeneca teaming up with Max Planck Institute to advance R&D
The focus will be on metabolic and cardiovascular diseases.
By Nicole Gray • July 9, 2014
Previous
